4A3 Stock Chart & Stats
€9.12
-€0.08(-1.10%)
At close: 4:00 PM EST
€9.12
-€0.08(-1.10%)
Day’s Range― - ―
52-Week Range€4.30 - €10.15
Previous CloseN/A
Volume0.00
Average Volume (3M)2.09K
Market Cap
€1.02B
Enterprise Value€819.68
Total Cash (Recent Filing)€454.04M
Total Debt (Recent Filing)€15.10M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Aug 19, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding134,096,570
10 Day Avg. Volume551
30 Day Avg. Volume2,092
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.26
Price to Sales (P/S)22.65
P/FCF Ratio-6.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.24Price Target Upside89.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.5
Revenue Forecast (FY)€33.31M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet, Low LeverageImmatics' extremely low debt-to-equity provides durable financial flexibility to fund R&D, pursue partnerships, or bridge financing rounds without near-term solvency risk. This reduces refinancing pressure and preserves optionality for strategic investments over the next several quarters.
Promising Phase 1 Clinical DataRobust Phase 1 responses and durable control in heavily pretreated cohorts materially de-risk Immatics' lead TCR programs. Positive, durable clinical signals support advancement to Phase 2, strengthen partner interest, and increase the chance of future milestone and royalty revenues over the medium term.
Shareholder Support & Governance ContinuitySmooth AGM approvals, board continuity and a new incentive plan align management with shareholders and preserve capital-management tools. This governance stability supports execution of long-term clinical and partnership strategies and helps retain talent through program development stages.
Bears Say
High Cash Burn & Negative Free Cash FlowSustained large negative operating and free cash flows indicate material funding needs and shorten the runway absent new partner deals or financings. Persistent cash burn raises dilution and execution risk, constraining the firm's ability to invest selectively over the coming quarters.
Volatile, Declining Collaboration RevenueHeavy reliance on collaboration income that can fall sharply creates structural revenue volatility. A meaningful drop in partner receipts alongside rising R&D spend weakens operating flexibility and increases reliance on external financing or new deals to sustain program advancement.
Weak Profitability And Negative ReturnsSteep revenue decline and deeply negative margins indicate current operations cannot cover costs, eroding shareholder capital over time. Negative returns and volatile earnings reduce internal funding capacity and heighten dilution risk if corrective revenue or milestone inflection doesn't occur within months.
Immatics News
4A3 FAQ
What was Immatics N.V.’s price range in the past 12 months?
Immatics N.V. lowest stock price was €4.30 and its highest was €10.15 in the past 12 months.
What is Immatics N.V.’s market cap?
Immatics N.V.’s market cap is €1.02B.
When is Immatics N.V.’s upcoming earnings report date?
Immatics N.V.’s upcoming earnings report date is Aug 19, 2026 which is in 19 days.
How were Immatics N.V.’s earnings last quarter?
Immatics N.V. released its earnings results on May 12, 2026. The company reported -€0.43 earnings per share for the quarter, missing the consensus estimate of -€0.396 by -€0.034.
Is Immatics N.V. overvalued?
According to Wall Street analysts Immatics N.V.’s price is currently Undervalued.
Does Immatics N.V. pay dividends?
Immatics N.V. does not currently pay dividends.
What is Immatics N.V.’s EPS estimate?
Immatics N.V.’s EPS estimate is -0.42.
How many shares outstanding does Immatics N.V. have?
Immatics N.V. has 134,096,570 shares outstanding.
What happened to Immatics N.V.’s price movement after its last earnings report?
Immatics N.V. reported an EPS of -€0.43 in its last earnings report, missing expectations of -€0.396. Following the earnings report the stock price went down -3.1%.
Which hedge fund is a major shareholder of Immatics N.V.?
Currently, no hedge funds are holding shares in DE:4A3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immatics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€17.24 (89.05% Upside)
€17.24 (89.05% Upside)
Blogger Sentiment
Bullish
DE:4A3 Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.70%
Trailing 12-Months
Company Description
Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
4A3 Stock 12 Month Forecast
Average Price Target
€17.24
▲(89.05% Upside)